Photos can pop when one area is in sharp focus and the other blurry, providing the impression of depth in a two-dimensional image that matches how our eyes focus on objects, even though we don’t ...

b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

Learn the secrets behind bold shape layers, smooth camera transitions, and the new cinematic depth of field features in After Effects Beta. #AfterEffects #MotionGraphics #VoxStyle Coffee linked to ...

Laurence Wall is a Contributor at DualShockers who has been writing professionally since 2022 and covering games since 2023. He primarily writes guides and lists, with a focus on indie games, RPGs, ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Getting a depth module in Subnautica 2 increases your tadpole submarine's depth resistance and lets you explore further without having to worry about finding oxygen spots. However, you'll reach the ...

Iranian strikes and a blockade have paralyzed Qatar’s gas engine, creating a technical bottleneck likely to stall exports for years. By River Akira Davis River Davis reported this article from Doha, ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...